Lilly powers through final stretch in critical Alzheimer's race

Following Eisai’s successful phase 3 readout of its Alzheimer’s disease treatment lecanemab, the pressure—and optimism—is mounting for top competitor Eli Lilly.

On the company’s third-quarter earnings call Tuesday, executives heralded those results, which found a 27% reduction in clinical decline among treated patients with early Alzheimer’s, as providing additional validation of the amyloid beta hypothesis that’s driven the development of Lilly's own donanemab.